Alnylam Pharmaceuticals Stock Fundamentals
| ALNY Stock | USD 246.80 1.99 0.80% |
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
At this time, Alnylam Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Alnylam | Select Account or Indicator |
Alnylam Pharmaceuticals Company Current Valuation Analysis
Alnylam Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alnylam Pharmaceuticals Current Valuation | 30.35 B |
Most of Alnylam Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Alnylam Pharmaceuticals has a Current Valuation of 30.35 B. This is 111.33% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 82.59% lower than that of the firm.
Alnylam Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alnylam Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Alnylam Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alnylam Pharmaceuticals competition to find correlations between indicators driving Alnylam Pharmaceuticals's intrinsic value. More Info.Alnylam Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Alnylam Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alnylam Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Alnylam Pharmaceuticals' Earnings Breakdown by Geography
Alnylam Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.Alnylam Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Alnylam Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 30.35 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Shares Owned By Institutions | 98.00 % | ||||
| Number Of Shares Shorted | 3.7 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 983.88 X | ||||
| Price To Sales | 15.20 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (258.24 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 4.60 X | ||||
| Earnings Per Share | (2.62) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 301.21 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 31.83 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 102.8 M | 119.3 M | |
| Total Revenue | 1.8 B | 1.9 B | |
| Cost Of Revenue | 310.4 M | 178.7 M | |
| Stock Based Compensation To Revenue | 0.12 | 0.12 | |
| Sales General And Administrative To Revenue | 0.44 | 0.41 | |
| Research And Ddevelopement To Revenue | 0.55 | 0.52 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 14.64 | 15.37 | |
| Ebit Per Revenue | (0.15) | (0.16) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.